• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination
Publication date: June 2018Source: Current Opinion in Virology, Volume 30Author(s): Claudia Dembek, Ulrike Protzer, Michael RoggendorfThe currently used nucleoside analogs (i.e. entecavir and tenofovir) with high barrier-to-resistance efficiently suppress viral replication, limit inflammation and reduce the sequelae of chronic hepatitis B, but cannot cure the disease and thus have to be applied long-term. Therapeutic vaccination as an approach to cure chronic hepatitis B has shown promising pre-clinical results, nevertheless the proof of its efficacy in clinical trials is still missing. This may be partially due to subopti...
Source: Current Opinion in Virology - July 10, 2018 Category: Virology Source Type: research

New treatments to reach functional cure: Virological approaches
Publication date: Available online 22 May 2017 Source:Best Practice & Research Clinical Gastroenterology Author(s): David Durantel Current therapies of chronic hepatitis B (CHB) remain limited to pegylated-interferon-alpha (pegIFN-α) or any of the five approved nucleos(t)ide analogues (NA). If viral suppression can be achieved in the majority of patients with the high-barrier-to-resistance new-generation of NA, i.e. entecavir and tenofovir, HBsAg loss is achieved by PEG-IFN-α and/or NA in only 10% of patients, after a 5-year follow-up. Attempts to improve the response by administering two different NA or a combi...
Source: Best Practice and Research Clinical Gastroenterology - May 22, 2017 Category: Gastroenterology Source Type: research